Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Revenue: 2021-2025

Historic Revenue for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Sep 2025 value amounting to $118.7 million.

  • Tarsus Pharmaceuticals' Revenue rose 146.68% to $118.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $366.1 million, marking a year-over-year increase of 182.44%. This contributed to the annual value of $183.0 million for FY2024, which is 948.62% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Revenue stood at $118.7 million, which was up 15.62% from $102.7 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Revenue peaked at $118.7 million during Q3 2025, and registered a low of -$815,000 during Q2 2023.
  • In the last 3 years, Tarsus Pharmaceuticals' Revenue had a median value of $40.8 million in 2024 and averaged $45.4 million.
  • Its Revenue has fluctuated over the past 5 years, first crashed by 151.05% in 2022, then surged by 5,107.73% in 2024.
  • Tarsus Pharmaceuticals' Revenue (Quarterly) stood at $338,000 in 2021, then skyrocketed by 2,858.58% to $10.0 million in 2022, then soared by 30.76% to $13.1 million in 2023, then skyrocketed by 407.86% to $66.4 million in 2024, then surged by 146.68% to $118.7 million in 2025.
  • Its last three reported values are $118.7 million in Q3 2025, $102.7 million for Q2 2025, and $78.3 million during Q1 2025.